News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bavarian Nordic (BAVA.CO) Announces First Patient Treated In A Phase 2 Study Evaluating Its Immunotherapy Candidate CV-301 In Bladder Cancer


4/28/2014 8:58:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KVISTGAARD, Denmark, April 28, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the first patient has now been treated in a randomized, prospective Phase 2 study of its active immunotherapy candidate CV-301 in bladder cancer.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES